Abstract: -Galactosidase is a widely used reporter enzyme, but although several substrates are available for in vitro detection, its application for in vivo optical imaging remains a challenge. To obtain a probe suitable for in vivo use, we modified our previously developed activatable fluorescence probe, TG-Gal (J. Am. Chem. Soc. 2005, 127, 4888-4894), on the basis of photochemical and photophysical experiments. The new probe, AM-TG-Gal, provides a dramatic fluorescence enhancement upon reaction with -galactosidase, and further hydrolysis of the ester moiety by ubiquitous intracellular esterases affords a hydrophilic product that is well retained within the cells without loss of fluorescence. We used a mouse tumor model to assess the practical utility of AM-TG-Gal, after confirming that tumors in the model could be labeled with an avidin--galactosidase conjugate. This conjugate was administered to the mice in vivo, followed by AM-TG-Gal, and subsequent ex vivo fluorescence imaging clearly visualized intraperitoneal tumors as small as 200 µm. This strategy has potential clinical application, for example, in video-assisted laparoscopic tumor resection.
Introduction
Marker enzymes are widely used to identify cell types or specific haptens, to examine transcription regulation or to evaluate the efficiency of transfection experiments. Escherichia coli -galactosidase is well characterized and extensively used as a marker enzyme in enzyme-linked immunosorbent assays (ELISA), [1] [2] [3] in situ hybridizations, 4-6 classification of mycobacteria, 7 and gene expression studies. [8] [9] [10] [11] This enzyme is especially useful for studying gene expression because of its stability, high turnover rate, and ease of conjugation and detection, as well as the absence of endogenous -galactosidase activity in eukaryotic cells. A range of substrates has been developed including colorimetric, 12,13 fluororescence, [14] [15] [16] [17] [18] [19] chemiluminescence, 20, 21 and paramagnetic probes, 22 though they have mostly been used in in Vitro systems, with only a few successful applications in ViVo. [23] [24] [25] Zentralbl Bakteriol. 1994, 280, 476-87. (8) Nolan, G. P.; Fiering, S.; Nicolas, J.-F.; Herzenberg, L. A. Proc. Natl. Acad. Sci. U.S.A. 1988 , 85, 2603 -2607 . (9) Latham, K. A.; Haugland, R. P. Anal. Biochem. 1999, 273, 41-48. (19) Corey, P. F.; Trimmer, R. W.; Biddlecom, W. G. Angew. Chem., Int. Ed. Engl. 1991 , 30, 1646 -1648 Takayasu, S.; Maeda, M.; Tsuji, A. J. Immunol. Methods 1985, 83, 317-325. (21) Arakawa, H.; Maeda, M.; Tsuji, A. Anal. Biochem. 1991, 199, 238-42. (22) In our previous work, we focused on simple, rapid, and sensitive detection of -galactosidase activity and developed a highly sensitive fluorescence probe for -galactosidase, TGGal (Scheme 1a) . 26 This probe was rationally designed to show a dramatic fluorescence activation (up to 440-fold) upon reaction with -galactosidase and was successfully used to visualize -galactosidase activity in living cells. We considered that such probes might be suitable to visualize tumors in ViVo. For example, in the clinical field, video-assisted laparoscopic surgery is becoming one of the standard methods for resecting metastases, 27 and it already relies on optical cameras that could easily be adapted to employ fluorescence imaging. 28 Probes such as TG-Gal have appropriate characteristics (high molar extinction coefficient and high fluorescence quantum yield (Φ fl ) in aqueous media after reaction with the target enzymes) for visualization of surface tumors such as intraperitoneal tumors, for which brightness of the fluorophores is more important than long-wavelength excitability, as the light does not need to penetrate the skin and tissues. Our aim in the present work was to design a TG-Gal-based probe that would be suitable for in ViVo tumor imaging and to test its suitability for this purpose in an animal tumor model. TG-Gal itself was unsuitable, as its hydrophobic fluorescent hydrolysis product is easily washed out from cells ( Figure 1a ). We therefore designed and synthesized a new probe, AM-TG-Gal. Like TG-Gal, AM-TGGal shows a dramatic fluorescence enhancement upon hydrolysis with -galactosidase. Further, the ester moiety of its hydrolysis product, AM-TG, is cleaved by ubiquitous intracellular esterases, generating a hydrophilic product that is well retained within the cells without loss of fluorescence. To examine whether AM-TG-Gal would indeed be suitable for in ViVo tumor imaging, we used the following two-step strategy in a mouse tumor model. First, an avidin--galactosidase conjugate was administered to the mice to target the enzyme to tumors, and then AM-TG-Gal was administered. Scheme 1. Reaction Schemes of Our Fluorescence Probes with -Galactosidase and Intracellular Esterase a a (a) Reaction of our previously reported -galactosidase probe, TG-Gal, with -galactosidase. (b) Newly developed -galactosidase substrates bearing an esterase-sensitive methylester, 1 Me -Gal, 2 Me -Gal, and 3 Me -Gal. (c) Our newly developed fluorescence probe, AM-TG-Gal, which shows a large fluorescence increase upon reaction with -galactosidase and is further hydrolyzed by intracellular esterase to the free carboxylate, which is well retained in the cells without loss of fluorescence.
feasibility of this approach to tumor imaging, which we believe has potential clinical applicability, for example in video-assisted laparoscopic tumor resection.
Results and Discussion
Design and Synthesis of New Probes with Improved Cellular Retention. We aimed to modify TG-Gal to obtain sufficient intracellular retention in the living cells by adopting the strategy of introducing an acetoxymethyl (AM) ester group. 29, 30 We anticipated that the AM-derivatized -galactosidase probe would be hydrolyzed both by -galactosidase to show large fluorescence activation and by ubiquitous intracellular esterases to yield the hydrophilic fluorophore with a free carboxylate group, which would not readily leak from the cells.
From the synthetic point of view, we first thought it would be simple to introduce a methoxycarbonyl methoxy group instead of the methoxy group of TG-Gal. According to Scheme 2, we synthesized 1 Me -Gal. Although 1 Me (the hydrolysis product of 1 Me -Gal) is highly fluorescent (Φ fl ) 0. Gal had a relatively high background fluorescence (Φ fl ) 0.069), so the fluorescence enhancement after activation was relatively modest (46-fold) (Table 1, Scheme 1b).
In order to understand this result, we have to consider the mechanism underlying the fluorescence off/on switching of TGGal, i.e., intramolecular photoinduced electron transfer (PeT), which is a nonradiative pathway from the excited-state of the fluorophore. As we demonstrated in our previous paper, fluorescein derivatives, including TokyoGreens, can be considered to consist of two functional components from the viewpoint of fluorescence, namely a benzene moiety which is the electron donor and a xanthene moiety which is the fluorophore (Scheme 1a). 31, 32 Moreover, the oxidation potential of the benzene moiety can greatly influence the efficiency of PeT, and m-methoxytoluene, the benzene moiety of TG-Gal, has the most suitable oxidation potential as an electron donor (1.66 V vs SCE, Table  2 ) in order to convert the change in reduction potential of the xanthene moiety induced by -galactosidase-assisted hydrolysis to the maximal change in fluorescence intensity. 26 Therefore, we measured the oxidation potential of m-methoxycarbonylmethoxytoluene, the benzene moiety of 1 Me -Gal (Bn(1 Me )), and found that the oxidation potential had been altered to a higher value (1.77 V vs SCE, Table 2 ) by the introduction of the electron-withdrawing methoxycarbonyl group with a short methylene linker, and this accounted for the increase of the background fluorescence of 1 Me -Gal. The calculated energy level of the highest occupied molecular orbital (HOMO), which is known to be linearly correlated with measured oxidation potential, supported this view (-0.2141 hartree for m-methoxytoluene and -0.2207 hartree for Bn(1 Me )) ( Table 2) .
Thus, we employed a strategy to lower the oxidation potential of Bn(1 Me ) to a value similar to that of m-methoxytoluene (1.66 V vs SCE) by introducing an electron-donating group. The oxidation potential of m-methoxycarbonylmethoxyanisole (Bn-(2 Me )), in which the methyl group of Bn(1 Me ) is replaced with a methoxy group, proved to be sufficiently small to suppress the background fluorescence (1.57 V vs SCE, Table 2 ) via the PeT pathway. Thus, we designed and synthesized 2 Me -Gal according to Scheme 3. As we expected, 2 Me -Gal showed low background fluorescence (Φ fl ) 0.004), whereas 2 Me (the hydrolysis product of 2 Me -Gal) showed strong fluorescence (Φ fl ) 0.67) (Table 1) . Thus, the fluorescence enhancement is 410-fold. Unfortunately, however, the fluorescence intensity of 2 Me was altered by esterase activity, because hydrolysis of the ester group lowered the oxidation potential too much, which led to quenching of the fluorescence output of 2 (Φ fl ) 0.32), the final fluorescent species generated from 2 Me -Gal (Scheme 1b, Table 1, Figure 2 ). For the reliable fluorescence detection of -galactosidase activity, the fluorescence should be unaffected by cleavage of the ester.
The solution we adopted was to reduce the electronwithdrawing effect of the methoxycarbonyl group of Bn(1 Me ) by lengthening the methylene chain between the methoxycarbonyl group and the benzene moiety. We calculated the HOMO energy levels of the benzene moiety with various lengths of methylene chain at the B3LYP/6-31G level and predicted that a HOMO level similar to that of m-methoxytoluene could be achieved by inserting three or four methylene units between the methoxycarbonyl group and the benzene moiety ( Table 2) . Oxidation potentials of m-methoxycarbonylbutyloxytoluene (Bn-(3 Me )) measured by cyclic voltammetry were consistent with this expectation (1.62 V vs SCE, Table 2 ). According to Scheme 4, we synthesized 3 Me -Gal with four methylene units. The background fluorescence of 3 Me -Gal was successfully suppressed (Φ fl ) 0.009), while the hydrolysis product of 3 MeGal (3 Me ) emits sufficiently strong fluorescence (Φ fl ) 0.85) (Scheme 1b, Table 1 ). The fluorescence enhancement ratio that can be obtained with 3 Me -Gal is approximately 360-fold. Moreover, its fluorescence was independent of the esterase activity (Φ fl of 3 was 0.85, Figure 2 ). Therefore, we derivatized 3 Me -Gal to the AM ester, which was designated AM-TG-Gal (Scheme 5). As expected, AM-TG-Gal shows almost no fluorescence (Φ fl ) 0.005) but is converted by -galactosidase to highly fluorescent AM-TG (Φ fl ) 0.86), affording a 470-fold fluorescent enhancement (Scheme 1c, Table 1, Figure 3 ). Thus, we finally succeeded in developing a highly sensitive fluorescence probe for -galactosidase with an esterase-sensitive moiety that could be removed without loss of the strong fluorescence, by finely tuning the oxidation potential to retain the highly activatable character of TG-Gal.
Relationship between Oxidation Potential and Fluorescence Quantum Yield. We plotted the fluorescence quantum yields of the anionic and neutral forms of 1 Me , 2 Me , and 3 Me (the scaffold fluorophores of 1 Me -Gal, 2 Me -Gal, and 3 MeGal) on a graph showing the relationship between the oxidation potential and fluorescence quantum yield (Φ fl ) of previously reported TokyoGreen derivatives ( Figure 4 , Table 3 ). 26 All the values including that of 1 Me , 2 Me , and 3 Me can be fitted with the Marcus equation. It can be seen that 3 Me lies between the fluorescence off/on thresholds of the anionic and neutral forms, indicating that it is the most suitable scaffold fluorophore for developing a highly sensitive fluorescence probe with enhanced cellular retention. This result also confirms that the previously reported design strategy is valid for developing new probes with desirable features. Me -Gal, and AM-TG-Gal were measured in 100 mM sodium phosphate buffer, pH 7.4, containing 0.1% DMSO as a cosolvent. Data for 1 Me , 2 Me , 3 Me , 1, 2, 3, and AM-TG were measured in 100 mM sodium phosphate buffer, pH 9.0, containing 0.1% DMSO as a cosolvent. b For determination of the fluorescence quantum yield, fluorescein in 100 mM aq. NaOH (0.85) was used as a fluorescence standard. 39 c Fluorescence enhancement represents the ratio of fluorescence intensity at 509-511 nm before and after hydrolysis by -galactosidase. Cellular Retention. We next examined whether or not the newly developed AM-TG-Gal is better retained in living cells as compared with TG-Gal. HEK293 cells expressing -galactosidase were incubated with 10 µM AM-TG-Gal, and fluorescence images were captured before and after the washing of the cells ( Figure 1b ). As expected, washing caused little change in the fluorescence, in contrast with the case of TGGal. This difference can be explained in terms of superior retention of the ultimate hydrolysis product of AM-TG-Gal in the living cells.
Targeting of -Galactosidase to Tumor Cells. We next tried to apply AM-TG-Gal to visualize intraperitoneal tumors in mice. For this purpose, we adopted a two-step procedure, employing a tumor-targeting avidin--galactosidase conjugate (avidin--galactosidase) to localize -galactosidase to cancer cells in ViVo, 33,34 followed by the administration of AM-TG- (2) MeI; (b) aq. NaOH, MeOH; (c) TBDMS-Cl, imidazole, DMF; (d) 3,6-bis(tert-butyldimethylsilanyloxy)xanthen-9-one, t-BuLi, THF; (e) TBAF, THF; (f) methyl bromoacetate, Cs2CO3, DMF; (g) 2,3,4,6-tetra-O-acetyl-R-D-galactopyranosyl bromide, Cs2CO3, DMF; (h) NaOMe, MeOH; (i) aq. NaOH, MeOH.
Gal. Avidin was chosen based on its high affinity for lectins on the surface of several human ovarian cancer cell lines, including SHIN3 cells. [35] [36] [37] The tumor model in mice was prepared as reported. 38 As a first step, we examined whether avidin--galactosidase could be targeted to SHIN3 cells in ViVo by injecting it intraperitoneally into mice bearing peritoneal SHIN3 tumors. After 24 h, the organs were harvested and stained with X-Gal. After further incubation for 2 h, a blue precipitate was observed only in the disseminated tumor, confirming that avidin--galactosidase can be efficiently targeted to SHIN3 cells in ViVo without loss of the enzymatic activity ( Figure 5 ).
Fluorescence Detection of Tumors in ViWo. We next tried to visualize tumors prelabeled with avidin--galactosidase by employing AM-TG-Gal. In mice intraperitoneally implanted with SHIN3 and pretreated with avidin--galactosidase (ip), intraperitoneal administration of AM-TG-Gal followed by incubation for 1 h revealed strongly fluorescent spots in the peritoneal cavity (Figure 6a and 6b) . Although the incubation time required for imaging is likely to vary depending on the size of the tumor, 1-h incubation produced clearer fluorescence signals than the 30-min incubation in our experiment. Small tumors on the mesenterium were clearly seen (Figure 6c ), and fluorescence microscopy revealed spots as small as 200 µm (Figure 6d ). The fluorescence enhancement at microfoci over the surrounding tissues on the mesenterium is up to 33-fold (Supporting Information Figure S1 ). In contrast, almost no fluorescence activation could be observed in a normal, tumorfree mouse treated with avidin--galactosidase and AM-TGGal (Supporting Information Figure S2 ). Mice given TG-Gal also showed a marked fluorescence increase in the peritoneal cavity, but this was unlikely to have been confined to tumors, owing to the leakage of the fluorescent product derived from TG-Gal (Figure 6e) . Indeed, the fluorescence signal produced by AM-TG-Gal at the tumors was not decreased by washing, in contrast to the case with TG-Gal, suggesting that our strategy of using the hydrolyzable AM moiety did indeed improve cellular retention of the fluorescent product (Figure 7) . Staining of tissue with X-Gal showed a similar distribution to that of the fluorescence signal produced by AM-TG-Gal, indicating that the fluorescence signal was colocalized with the -galactosidase activity (Figure 8) . As regards the specificity of the staining, it has previously been shown that at least 99% of the small spots in the peritoneal cavity in this tumor model are tumors (Supporting Information Figure S3 ). 35 These results suggest that AM-TG-Gal had been hydrolyzed both by the SHIN3-targeted -galactosidase, leading to fluorescence activation, and by intraplasmic esterase, resulting in good retention within cells.
Conclusion
There is increasing interest in in ViVo optical imaging of -galactosidase in the biological and clinical fields but with limited success so far. [23] [24] [25] We have developed AM-TG-Gal as a highly sensitive fluorescence probe for -galactosidase that is suitable for targeted tumor imaging in ViVo. It represents a development of our previously reported fluorescence probe for -galactosidase, 26 modified by introducing AM ester into TGGal through a precisely optimized linker while retaining the advantageous optical properties of TG-Gal. AM-TG-Gal exhibits a drastic fluorescence enhancement upon reaction with -galactosidase and is well retained intracellularly after hydrolysis by ubiquitous intracellular esterases without loss of fluorescence. Moreover, we devised a two-step strategy for highly activatable optical imaging of intraperitoneal tumor cells without the need for prior transfection of reporter enzymes. First, a conjugate of a tumor-targeting molecule and the enzyme, avidin--galacotosidase, is administered and binds via avidin to the tumor cell surface. Second, AM-TG-Gal is administered and is hydrolyzed to AM-TG by -galactosidase bound to the tumor cells. AM-TG exhibits both highly activated fluorescence and enhanced permeability and is readily transferred into nearby tumor cells, where it is hydrolyzed to the free carboxylate by cytoplasmic esterases. This procedure provides a tumor-specific, long-lived, and highly activated fluorescence signal. Studies to examine the feasibility of using this approach in video-assisted laparoscopic surgery are in progress. The present results indicate that chemistry-based fine-tuning of chemical properties (both fluorescence and cell permeability) could be the key to the development of small-molecular "magic bullets" in the fields of biology and clinical medicine, and we believe that the range of potential applications of our new probe is enormous.
Experimental Section
All procedures were carried out in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996) , National Research Council, and approved by the National Cancer Institute Animal Care and Use Committee. All experiments were carried out at 25°C, unless otherwise specified.
Materials and Instruments. Chemicals used for organic synthesis were of the best grade available, supplied by Tokyo Chemical Industries, Wako Pure Chemical or Aldrich Chemical Co., and were used without further purification. 1 H NMR and 13 C NMR spectra were recorded on a JNM-LA300 (JEOL) instrument at 300 and 75 MHz and on a JNM- a Data for the anionic form were measured in 100 mM sodium phosphate buffer, pH 9.0, containing 0.1% DMSO as a cosolvent. b Data for the neutral form were measured in 100 mM sodium phosphate buffer, pH 3.4, containing 0.1% DMSO as a cosolvent. For determination of the fluorescence quantum yield, fluorescein in 100 mM aq. NaOH (0.85) was used as a fluorescence standard. 39 AL400 (JEOL) instrument at 400 MHz. Mass spectra (MS) were measured with an SX-102A (JEOL) for EI, an MS700 (JEOL) for FAB, and a JMS-T100LC (JEOL) for ESI-TOF.
UV/vis and Fluorescence Analysis. For the absorption or fluorescence measurement, compounds were dissolved in dimethyl sulfoxide (DMSO, fluorometric grade, Dojindo) to obtain 10 mM stock solutions. These stock solutions were diluted with buffer as specified in the figure legends to the desired concentration. For determination of the quantum efficiency of fluorescence (Φ fl), fluorescein in 100 mM aq. NaOH (Φfl ) 0.85) was used as a fluorescence standard.
39 -Galactosidase and porcine liver esterase were purchased from Sigma-Aldrich Japan K.K. All absorption spectra were obtained with a 8453 UV/vis spectrometer (Agilent) or with a UV-1600 UV/vis spectrometer (Shimadzu). All fluorescence spectra were obtained with an LS-55 fluorescence spectrometer (Perkin-Elmer) or an F4500 fluorescence spectrometer (Hitachi).
Cyclic Voltammetry. Cyclic voltammetry was performed on a 600A electrochemical analyzer (ALS). A three-electrode arrangement in a single cell was used for the measurements: a Pt wire as the auxiliary electrode, a glassy carbon electrode as the working electrode, and a Ag/Ag + electrode as the reference electrode. The sample solutions contained a 1.0 mM sample and 100 mM tetrabutylammonium perchlorate (TBAP) as a supporting electrolyte in acetonitrile, and argon was bubbled for 10 min before each measurement. Obtained potentials (vs Ag/Ag + ) were converted to those vs SCE by adding 0.248 V.
Photochemical Calculation. HOMO energy levels were calculated at the B3LYP/6-31G level with Gaussian 98W. Intracellular Retention Assay. HEK293 cells expressing -galactosidase were incubated with a 10 µM solution of TG-Gal or AM-TG-Gal in physiological salt solution, pH 7.4, containing 150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, and 0.1% glucose (PSS), and 0.1% DMSO as a cosolvent for 2 h. Then, confocal fluorescence images and DIC images were captured before and after washing with PSS. The images were obtained with an Olympus fluoview system using an IX81 inverted microscope, an Ar ion laser, and a PlanApo 40x/1.40 objective lens (Olympus, Tokyo, Japan). The excitation wavelength was 488 nm, and the emission wavelength was 510-550 nm.
Mouse Preparation. The intraperitoneal tumor model was prepared as previously reported. 38 Briefly, 2 × 10 6 SHIN3 cancer cells suspended in PBS(-) were injected intraperitoneally into female nude mice (National Cancer Institute Animal Production Facility, Frederick, MD). Experiments with these tumor-harboring mice were performed at 10-13 days after dissemination, when numerous small, intraperitoneally disseminated tumors had formed, especially around the stomach, the subphrenic region, at the hepatic and splenic hila, and on the mesentery.
Biodistribution of Avidin--galactosidase in ViWo. Avidin--galactosidase (100 µg) in PBS(-) was injected intraperitoneally into tumor-bearing mice. After 20 h, the mice were sacrificed by exposure to CO 2 gas. The main internal organs (tumor, mesentery, intestine, stomach, liver, kidney, spleen, lung, heart) were removed for routine X-Gal staining.
Fluorescence Imaging of Tumors in a Mouse Tumor Model.
Avidin--galactosidase (100 µg) in PBS(-) was injected intraperitoneally into a tumor-bearing mouse, which was left for 16-23 h. Then, a 3.3 µM solution of AM-TG-Gal was injected. After 1 h, the mouse was sacrificed under anesthesia, and the abdominal walls were removed. Fluorescence images in the peritoneal cavity were captured with a Maestro In-Vivo Imaging System (CRI Inc., Woburn, MA). The excitation wavelength was 445-490 nm. Spectral unmixing was performed to obtain the fluorescence unmixed images. Fluorescence images of tumor nodules on the mesentery were captured with a BX51 
Synthesis of 2-Bromo-5-(tert-butyldimethylsilyloxy)toluene (1).
A mixture of 4-bromo-3-methylphenol (2 g, 10.7 mmol), tert-butyldimethylsilyl chloride (TBDMS-Cl) (4.8 g, 30 mmol), and imidazole (3.6 g, 50 mmol) in dry DMF (10 mL) was stirred at room temperature under argon for 3 h. The solvent was concentrated under reduced pressure. The residue was diluted with water and extracted with CH2-Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated to give 1 as a colorless clear oil (3.04 g, 95%).
1 H NMR (300 MHz, CDCl3) δ 7.33 (d, 1H, J ) 8.6 Hz), 6.72 (d, 1H, J ) 2.9 Hz), 6.53 (dd, 1H, J ) 8.6 Hz, 2.9 Hz), 2.32 (s, 3H), 0.97 (s, 9H), 0.18 (s, 6H); 13 C NMR (75 MHz, CDCl3) δ 154. 88, 138.79, 132.76, 122.59, 119.10, 116.16, 25.64, 22.98, 18.18, -4.48 
Synthesis of 9-{1-[4-(tert-Butyldimethylsilyloxy)-2-methylphenyl]}-6-hydroxy-3H-xanthen-3-one (2).
A solution of 1 (1.28 g, 4.27 mmol) in distilled THF (10 mL) was cooled down to -78°C (dry ice-acetone). tert-Butyllithium in an n-pentane solution (4.5 mL, 6.57 mmol) was added dropwise to the reaction mixture using a syringe. 3,6-Bis-(tert-butyldimethylsilanyloxy)xanthen-9-one (1.07 g, 2.37 mmol) dissolved in distilled THF (20 mL) was added dropwise to the mixture using a syringe. The mixture was stirred at -78°C under argon for 30 min, then 2 N aq. HCl was added, and the red precipitate was collected by filtration. The precipitate was chromatographed on silica gel with CH 2Cl2-MeOH (100:3-100:5) as the eluent to give 2 as an orange powder (774.6 mg, 82%). Tumor imaging with TG-Gal, following pretreatment with avidin--galactosidase. Strong fluorescence was observed in the peritoneal cavity; however, this was unlikely to have been confined to tumors, owing to the rapid leakage of its fluorescent product. The unmixed fluorescence images (left) and white light images (right) of (a), (b), (c), and (e) were captured with a Maestro In-Vivo Imaging System (CRI Inc., Woburn, MA). To obtain the unmixed fluorescence images, spectral division was performed using the autofluorescence of intestine (yellow) and the fluorescence at the tumor (green). The fluorescence image (left) and DIC image (right) of (d) were captured with a BX51 microscope (Olympus USA, Melville, NY). temperature under argon for 2 h and then evaporated, and the residue was chromatographed on silica gel with CH2Cl2-MeOH (100:5-100: 7) as the eluent to give 3 as an orange powder (1.13 g, 58% 60, 168.75, 161.03, 160.78, 138.82, 134.65, 131.78, 122.84, 121.30, 118.66, 118.29, 114.30, 103.40, 20.25 Synthesis of 9-[1-(4-Methoxycarbonylmethoxy-2-methylphenyl)]-6-hydroxy-3H-xanthen-3-one (4) . To a mixture of 3 (60 mg, 0.18 mmol) and Cs2CO3 (400 mg, 1.2 mmol) in dry dimethylformamide (5 mL), methyl bromoacetate (17 µL, 0.18 mmol) was added. The reaction mixture was stirred at room temperature under argon overnight. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with CH2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with CH2-Cl2-MeOH (100:5) as the eluent to give 4 as a red powder (41.7 mg, 57%). (2 mL) was stirred at room temperature under argon overnight. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with CH2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with CH2Cl2-MeOH (100:3) as the eluent to give 5 as an orange powder (41.8 mg, 58%). 743.19519; found, 743.19309 . Synthesis of 9-[1-(4-Methoxycarbonylmethoxy-2-methylphenyl)]-6-hydroxy-3H-xanthen-3-one Mono--D-galactopyranoside (6). To a solution of 5 (5 mg, 6.9 µmol) in methanol (2 mL) a 5 M methanol solution of NaOMe (2 µL, 10 µmol) was added. The mixture was stirred at room temperature for 1 h and then neutralized with Amberlite IR-120 (H + ). The Amberlite IR-120 was filtered off, and the filtrate was evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (100:10) as the eluent to give 6 as an orange powder (2.4 mg, 62%).
1 H NMR (300 MHz, CD3OD) δ 7.36 (d, 1H, J ) 2.2 Hz), 7.18 (d, 1H, J ) 9.0 Hz), 7.17 (d, 1H, J ) 8.4 Hz), 7.15 (d, 1H, J ) 9.6 Hz), 7.07-7.12 (m, 1H), 7.06 (d, 1H, J ) 2.6 Hz), 7.00 (dd, 1H, J ) 8.4, 2.6 Hz), 6.61 (dd, 1H, J ) 9.6, 2.0 Hz), 6.47 (d, 1H, J ) 2.0 Hz), 5.10 (dd, 1H, J ) 7.7, 2.6 Hz), 4.84 (s, 2H), 3.92 (d, 1H, J ) 3.5 Hz), 3.82 (s, 3H), 3.73-3.89 (m, 4H), 3.62 (dd, 1H, J ) 9.7, 3.3 Hz), 2.03 (s, 3H). HRMS(ESI + ): calcd for [M + H] + , 553.17099; found, 553.16771.
Synthesis of 9-[1-(4-Carboxymethoxy-2-methylphenyl)]-6-hydroxy-3H-xanthen-3-one (7). To a solution of 4 (15 mg, 38 µmol) in methanol (4 mL) 2 M aq. NaOH (1 mL, 2 mmol) was added. The mixture was stirred at room temperature for 4 h and then neutralized with 2 N aq. HCl. The methanol was evaporated off, and the residue was diluted with H2O and extracted with CH2Cl2. The combined organic layer was evaporated, and the residue was chromatographed on silica gel with CH 2Cl2-MeOH (100:5) as the eluent to give 7 as an orange powder (12 mg, 83%).
1 H NMR (300 MHz, CD3OD) δ 7.00 (d, 1H, J ) 8. 4 Hz), 2H), 6.88 (d, 2H, J ) 
Synthesis of 2-Bromo-5-(toluene-4-sulfonyloxy)anisole (8).
A mixture of 4-bromoresorcinol (2.0 g, 10.5 mmol), p-toluenesulfonyl chloride (2.21 g, 11.6 mmol), and K2CO3 (4.4 g, 32 mmol) in dry acetone (150 mL) was refluxed overnight. MeI (1.3 mL, 21 mmol) was added, and the reaction mixture was refluxed overnight again. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with AcOEt three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na 2SO4, and evaporated to give 8 as a light pink oil (3.8 g, quant. 47, 156.25, 133.04, 113.19, 105.06, 103.03, 56.08, 25.64, 18.19, -4.45 . MS (EI): 356, 358 (M + ).
Synthesis of 4-Bromo-3-methoxyphenol (9). To a solution of 8 (3.08 g, 8.6 mmol) in distilled MeOH (100 mL) 2 N aq. NaOH (20 mL) was added. The solution was refluxed for 1.5 h, and then the solvent was evaporated. The obtained residue was neutralized with 2 N aq. HCl and extracted with CH2Cl2 three times. The organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated to give 9 as a clear oil (1.57 g, 89%). 
Synthesis of 2-Bromo-5-(tert-butyldimethylsilyloxy)anisole (10).
A mixture of 9 (1.57 g, 7.7 mmol), TBDMS-Cl (3.5 g, 23 mmol), and imidazole (2.6 g, 39 mmol) in dry DMF (10 mL) was stirred at room temperature under argon overnight. The solvent was concentrated under reduced pressure. The residue was diluted with water and extracted with CH2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with hexane-AcOEt (4:1) as the eluent to give 10 as a light yellow clear oil (1.88 g, 76.7%). 1 H NMR (300 MHz, CDCl3) δ 7.33 (d, 1H, J ) 8.6 Hz), 6.41 (d, 1H, J ) 2.6 Hz), 6.34 (dd, 1H, J ) 8.6 Hz, 2.6 Hz), 3.85 (s, 3H), 0.98 (s, 9H), 0.20 (s, 6H); 13 C NMR (75 MHz, CDCl3) δ 156. 46, 149.55, 145.61, 133.28, 132.03, 129.80, 128.59, 115.20, 109.92, 106.97, 56.34, 21.70 . MS (EI): 316, 318 (M + ).
Synthesis of 9-{1-[4-(tert-Butyldimethylsilyloxy)-2-methoxyphenyl]}-6-hydroxy-3H-xanthen-3-one (11). 10 (1.39 g, 4.4 mmol) was dissolved in distilled THF (10 mL), and the solution was cooled to -78°C (dry ice-acetone). tert-Butyllithium in n-pentane solution (4.5 mL, 6.57 mmol) was added dropwise to the reaction mixture, and then 3,6-bis(tert-butyldimethylsilanyloxy)xanthen-9-one (1.19 g, 2.6 mmol) dissolved in 20 mL of distilled THF was further added dropwise. The mixture was stirred at -78°C under argon for 30 min, and 2 N aq. HCl was added. The solvent was evaporated under reduced pressure to leave a residue, which was diluted with water and extracted with CH 2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The precipitate was chromatographed on silica gel with CH2Cl2-MeOH (100:5) as the eluent to give 11 as an orange powder (43.6 mg, 3.7%). Synthesis of 9-[1-(2-Methoxy-4-methoxycarbonylmethoxyphenyl)]-6-hydroxy-3H-xanthen-3-one (13). A mixture of 12 (22.7 mg, 68 µmol), bromomethyl acetate (6.27 µL, 68 µmol), and Cs2CO3 (66.5 mg, 204 µmol) was stirred at room temperature under argon overnight. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with CH2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with CH 2Cl2-MeOH (100:5) as the eluent to give 13 as an orange powder (17.4 mg, 63% Synthesis of 9-[1-(2-Methoxy-4-methoxycarbonylmethoxyphenyl)]-6-hydroxy-3H-xanthen-3-one Mono(2′,3′,4′,6′-tetra-O-acetyl--D-galactopyranoside) (14). A mixture of 13 (3.8 mg, 9.3 µmol), Cs2CO3 (38.4 mg, 117 µmol), and 2,3,4,6-tetra-O-acetyl-R-D-galactopyranosyl bromide (100 mg, 0.25 mmol) in dry DMF (2 mL) was stirred at room temperature under argon for 4.5 h. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with CH 2-Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with CH2Cl2-MeOH (100:3) as the eluent to give 14 as an orange powder (6.4 mg, 94.2% Synthesis of 9-[1-(2-Methoxy-4-methoxycarbonylmethoxyphenyl)]-6-hydroxy-3H-xanthen-3-one Mono--D-galactopyranoside) (15). To a solution of 14 (2 mg, 2.7 µmol) in methanol (1 mL) a 5 M methanol solution of NaOMe (2 µL, 5 µmol) was added. The mixture was stirred at room temperature for 1 h and then neutralized with Amberlite IR-120 (H + ). The Amberlite IR-120 was filtered off, and the filtrate was evaporated. The residue was chromatographed on silica gel with CHCl 3-MeOH (100:10) as the eluent to give 15 as an orange powder (0.74 mg, 48% Synthesis of 9-[1-(4-Carboxymethoxy-2-methoxyphenyl)]-6-hydroxy-3H-xanthen-3-one (16). To a solution of 13 (4.1 mg, 10 µmol) in methanol (1 mL) 2 N aq. NaOH (0.1 mL, 0.2 mmol) was added. The mixture was stirred at room temperature for 4 h and then neutralized with 2 N aq. HCl. The solvent was evaporated off, and the residue was subjected to reversed-phase preparative TLC (RP18W) with acetonitrile/water (1:1) as the eluent to give 16 as an orange powder (3 mg, 76% 
Synthesis of 9-{1-[4-(4-Methoxycarbonylbutyloxy)-2-methylphenyl]}-6-hydroxy-3H-xanthen-3-one (17).
To a mixture of 3 (63.8 mg, 0.20 mmol) and Cs2CO3 (400 mg, 1.2 mmol) in dry dimethylformamide (2 mL) methyl 5-bromovalerate (21 µL, 0.18 mmol) was added. The reaction mixture was stirred at room temperature under argon overnight. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with CH2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with CH 2Cl2-MeOH (100:5) as the eluent to give 17 as a red powder (53.7 mg, 62%). 1 H NMR (300 MHz, CDCl3) δ 7.10 (d, 2H, J ) 9.2 Hz), 7.07 (d, 1H, J ) 8.3 Hz), 6.91-6.84 (m, 4H), 6.81 (dd, 2H, J ) 9.2 Hz, 2.0 Hz), 4.06 (m, 2H), 3.70 (s, 3H), 2.45 (m, 2H), 2.02 (s, 3H), 1.88 (m, 4H); 13 C NMR (75 MHz, CDCl3) δ 175. 04, 174.08, 159.73, 157.43, 152.90, 137.67, 130.77, 130.21, 124.47, 121.80, 116.42, 115.57, 111.84, 103.68, 67.41, 53.35, 33.58, 28.54, 21.55, 19.83 , and 2,3,4,6-tetra-O-acetyl-R-D-galactopyranosyl bromide (100 mg, 0.25 mmol) in dry dimethylformamide (1 mL) was stirred at room temperature under argon overnight. The inorganic precipitate was filtered off, and the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with CH 2Cl2 three times. The combined organic solution was washed with water and saturated aq. NaCl, dried over Na2SO4, and evaporated. The residue was chromatographed on silica gel with AcOEt as the eluent to give 18 as an orange powder (25 mg, 78%). 1 H NMR (300 MHz, CDCl3) δ 7.08-6.80 (m, 7H), 6.57 (dd, 1H, J ) 9. To a solution of 18 (28 mg, 37 µmol) in methanol (5 mL) a 5 M methanol solution of NaOMe (10 µL, 50 µmol) was added. The mixture was stirred at room temperature for 1 h and then neutralized with Amberlite IR-120 (H + ). The Amberlite IR-120 was filtered off, and the filtrate was evaporated. The residue was subjected to reversedphase preparative TLC (RP18W) with acetonitrile/water (1:1) as the eluent to give 19 as an orange powder (7.4 mg, 34%). 1 H NMR (300 MHz, CD3OD) δ 7.37 (d, 1H, J ) 2.4 Hz), 7.19 (dd, 1H, J ) 8. Synthesis of 9-{1-[4-(4-Carboxybutyloxy)-2-methylphenyl]}-6-hydroxy-3H-xanthen-3-one (20). To a solution of 17 (9.3 mg, 21.5 µmol) in methanol (2 mL) 2 M aq. NaOH (0.5 mL, 1 mmol) was added. The mixture was stirred at room temperature for 4 h and then neutralized with 2 N aq. HCl. The methanol was evaporated off, and the residue was diluted with H2O and then extracted with CH2Cl2. The combined organic layer was evaporated, and the residue was chromatographed on silica gel with CH 2Cl2-MeOH (100:5) as the eluent to give 20 as an orange powder (7 mg, 78%). 1 H NMR (300 MHz, CD3OD) δ 7.11-7.16 (m, 3H), 7.03 (d, 1H, J ) 2.6 Hz), 6.98 (dd, 1H, J ) 8.4, 2.6 Hz), 6.70-6.75 (m, 4H), 4.10 (t, 2H, J ) 5.6 Hz), 2.40 (t, 2H, J ) 6.8 Hz),
